Retinal hemorrhages in anastrozole users

Optometry and Vision Science

Volumn 85, Issue 5, 2008, Pages E301-E308

  Eisner, Alvin ^a   Falardeau, Julie ^a   Toomey, Maureen d ^a   Vetto, John t ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aromatase inhibitor; Aspirin; Bisphosphonate; Breast cancer; Eye; Retina; Vascular

Indexed keywords

COHERENT LIGHT; ENDOCRINOLOGY; MICROBIOLOGY; OCCUPATIONAL RISKS; OPHTHALMOLOGY; PHOTOGRAPHY; TOMOGRAPHY;

AROMATASE INHIBITORS; BISPHOSPHONATES; BREAST CANCER; MEDICATION;

EYE PROTECTION;

ANASTROZOLE; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; AMENORRHEA; ANAMNESIS; ARTICLE; BLOOD PRESSURE MONITORING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLIMACTERIUM; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHOTOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; RETINA FOVEA; RETINA HEMORRHAGE;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MIDDLE AGED; NITRILES; PATIENT SELECTION; RETINAL HEMORRHAGE; RETROSPECTIVE STUDIES; TAMOXIFEN; TOMOGRAPHY, OPTICAL COHERENCE; TRIAZOLES;

EID: 43149105382     PISSN: 10405488     EISSN: 15389235     Source Type: Journal    
DOI: 10.1097/OPX.0b013e31816bea3b     Document Type: Article

References (43)

1. Buzdar AU. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis 2005;24:107-17.
2. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-7.
3. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001;92:37-45.
4. Osborne CK, Schiff R. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol 2005;95:183-7.
5. Clemons M, Coleman RE, Verma S. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 2004;30:325-32.
6. Ponzone R, Biglia N, Jacomuzzi ME, Mariani L, Dominguez A, Sismondi P. Antihormones in prevention and treatment of breast cancer. Ann NY Acad Sci 2006;1089:143-58.
7. Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol 2005;95:75-81.
8. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126-36.
9. Nilsson S, Gustafsson JA. Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol 2002;37:1-28.
10. Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg 2006;192:496-8.
11. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
12. Schnatz PF. Hormonal therapy: does it increase or decrease cardiovascular risk? Obstet Gynecol Surv 2006;61:673-81.
13. Klouche M. Estrogens in human vascular diseases. Ann NY Acad Sci 2006;1089:431-43.
14. Munaut C, Lambert V, Noel A, Frankenne F, Deprez M, Foidart JM, Rakic JM. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol 2001;85:877-82.
15. Chuo JY, Lee TY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DA. Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol 2006;142:931-7.
16. The Eye Disease Case-Control Study Group. Risk factors for idiopathic macular holes. Am J Ophthalmol 1994;118:754-61.
17. Evans JR, Schwartz SD, McHugh JD, Thamby-Rajah Y, Hodgson SA, Wormald RP, Gregor ZJ. Systemic risk factors for idiopathic macular holes: a case-control study. Eye 1998;12:256-9.
18. Weiss G, Skurnick JH, Goldsmith LT, Santoro NF, Park SJ. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 2004;292:2991-6.
19. la Cour M, Friis J. Macular holes: classification, epidemiology, natural history and treatment. Acta Ophthalmol Scand 2002;80:579-87.
20. Smiddy WE, Flynn HW Jr. Pathogenesis of macular holes and therapeutic implications. Am J Ophthalmol 2004;137:525-37.
21. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-8.
22. van Overdam KA, Bettink-Remeijer MW, Klaver CC, Mulder PG, Moll AC, van Meurs JC. Symptoms and findings predictive for the development of new retinal breaks. Arch Ophthalmol 2005;123:479-84.
23. Eisner A, Toomey MD, Falardeau J, Samples JR, Vetto JT. Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Cancer Res Treat 2007;106:161-70.
24. Eisner A, Toomey MD, Incognito LJ, O'Malley JP, Samples JR. Contrasting blue-on-yellow with white-on-white visual fields: roles of visual adaptation for healthy peri- or postmenopausal women younger than 70 years of age. Invest Ophthalmol Vis Sci 2006;47:5605-14.
25. Eisner A, Incognito LJ. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen. Vision Res 2006;46:1816-22.
26. Eisner A, O'Malley JP, Incognito LJ, Toomey MD, Samples JR. Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy. Curr Eye Res 2006;31:367-79.
27. Eisner A, Austin DF, Samples JR. Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 2004;88:125-30.
28. Eisner A, Samples JR. High blood pressure and visual sensitivity. J Opt Soc Am 2003;20:1681-93.
29. Wong TY, Klein R, Amirul Islam FM, Cotch MF, Couper DJ, Klein BE, Hubbard LD, Sharrett AR. Three-year incidence and cumulative prevalence of retinopathy: the atherosclerosis risk in communities study. Am J Ophthalmol 2007;143:970-6.
30. Chui TY, Yap MK, Chan HH, Thibos LN. Retinal stretching limits peripheral visual acuity in myopia. Vision Res 2005;45:593-605.
31. Hayreh SS, Jonas JB. Posterior vitreous detachment: clinical correlations. Ophthalmologica 2004;218:333-43.
32. Mayr FB, Jilma B. Current developments in anti-platelet therapy. Wien Med Wochenschr 2006;156:472-80.
33. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135:219-22.
34. Haverbeke G, Pertile G, Claes C, Zeyen T. Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. Bull Soc Belge Ophtalmol 2003;71-6.
35. Dowdy S, Wearden S. Statistics for Research. New York: Wiley; 1983.
36. Lund-Anderson H, Sander B. The vitreous. In: Kaufman PL, Alm A, eds. Adler's Physiology of the Eye: Clinical Application, 10th ed. St. Louis: Mosby; 2003:293-316.
37. Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 2005;95:143-9.
38. Yu T, Mitchell P, Berry G, Li W, Wang JJ. Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol 1998;116:83-9.
39. Klein R, Klein BE, Moss SE, Wang Q. Blood pressure, hypertension and retinopathy in a population. Trans Am Ophthalmol Soc 1993;91:207-22.
40. Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol 2005;26:101-5.
41. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006;20:1029-39.
42. Rodondi N, Vittinghoff E, Cornuz J, Butler J, Ding J, Satterfield S, Newman AB, Harris TB, Hulley SB, Bauer DC. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med 2005;118:1288.
43. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877-83.